3-rx.comCustomer Support3-rx.com
Find a product
    HomeAbout UsFAQContactHelp
 
   
 
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics
Online Pharmacy



Topiramate (toe-PYRE-a-mate) is used to help control some types of seizures in the treatment of epilepsy. This medicine cannot cure epilepsy and will only work to help control seizures for as long as you continue to take it.


Join our Mailing List

Men`s Health sites at Top100biz.com




Syndicate

You are here : 3-RX.com > Home > Cancer -

Calcium + vitamin D doesn’t curb colorectal cancer risk

CancerFeb 16, 06

In a large study of postmenopausal women, daily supplementation of calcium with vitamin D for 7 years did not reduce the risk of colorectal cancer, doctors report in The New England Journal of Medicine this week. However, a beneficial effect may be become apparent with longer follow-up, the authors note.

Past studies have linked calcium and vitamin D use with a reduced risk of colorectal cancer and, in polyp-prevention trials, this combination seemed to help prevent polyp recurrence. Whether this dietary intervention could actually help prevent colorectal cancer, however, was unclear.

To investigate, Dr. Jean Wactawski-Wende, from SUNY University at Buffalo in New York, and colleagues assessed the outcomes of 36,282 postmenopausal women who participated in a study in which they received calcium 500 mg with vitamin D 200 IU or matching placebos twice daily for 7 years.

During follow-up, the number of women who developed colorectal cancer was nearly the same in each group, hovering around 161.

Moreover, the tumors that developed in each group were similar in appearance and stage. Likewise, colorectal-cancer screening and abdominal symptoms were comparable in each group.

The investigators reason that the “long latency associated with the development of colorectal cancer, in concert with the 7-year duration of the trial, may have contributed to” the null finding.

In a related editorial, Dr. Michele R. Forman and Dr. Bernard Levin, from the M. D. Anderson Cancer Center in Houston, note that the doses of these substances “may have been too low to achieve the desired effect.”

SOURCE: The New England Journal of Medicine, February 16, 2006



Print Version
Tell-a-Friend

RELATED ARTICLES:
  U.S. study weighs lifetime risks from CT scans
  Cancer patients’ race may affect well-being
  New statistical model could help reduce breast-lesion biopsies
  Testing for cancer at home
  Tamoxifen easier on the brain than thought: study
  Cancer incidence and mortality drops among American men and women, according to annual report
  Iressa Proves Just as Effective as Chemotherapy for Lung Cancer
  Latinas more likely to regret breast cancer treatment decisions
  Cancer survival rates impact type of Web communities used by patients
  No Protective Effect on Cancer from Long-Term Vitamin E or Vitamin C Supplementation
  Genetics of aging and cancer resistance
  Scientists unravel breast cancer drug resistance

 


Advertisement
















Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site